An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex(®) (THC:CBD, nabiximols) oromucosal spray

The global exposure of Sativex(®) (Δ(9)-tetrahydrocannabinol [THC]:cannabidiol [CBD], nabiximols) is estimated to be above 45,000 patient-years since it was given marketing approval for treating treatment-resistant spasticity in multiple sclerosis (MS). An observational registry to collect safety da...

Descripción completa

Detalles Bibliográficos
Autores principales: Etges, Tilden, Karolia, Kari, Grint, Thomas, Taylor, Adam, Lauder, Heather, Daka, Brian, Wright, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5113923/
https://www.ncbi.nlm.nih.gov/pubmed/27956834
http://dx.doi.org/10.2147/TCRM.S115014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5113923/
https://www.ncbi.nlm.nih.gov/pubmed/27956834
http://dx.doi.org/10.2147/TCRM.S115014

Ejemplares similares